References
1. Campbell CM, Kahwash R. Will
Complement Inhibition Be the New Target in Treating COVID-19-Related
Systemic Thrombosis? Circulation. 2020;141(22):1739-41.
2. Maloney N, Martin I,
Szczepiorkowski ZM, Dunbar NM. Therapeutic plasma exchange for
thrombotic thrombocytopenic purpura with refractory thrombocytopenia.
Journal of clinical apheresis. 2018;33(3):436-8.
3. Iba T, Levy JH, Connors JM,
Warkentin TE, Thachil J, Levi M. The unique characteristics of COVID-19
coagulopathy. Critical Care. 2020;24(1):1-8.
4. Tadkalkar N, Prasad S, Gangodkar S,
Ghosh K, Basu A. Dengue Virus NS1 Exposure Affects von Willebrand Factor
Profile and Platelet Adhesion Properties of Cultured Vascular
Endothelial Cells. Indian J Hematol Blood Transfus. 2019;35(3):502-6.
5. Sadler JE. What’s new in the
diagnosis and pathophysiology of thrombotic thrombocytopenic purpura.
Hematology Am Soc Hematol Educ Program. 2015;2015(1):631-6.
6. Vacca VM, Jr. Acquired autoimmune
thrombotic thrombocytopenic purpura. Nursing. 2019;49(1):22-9.
7. Rogers HJ, Allen C, Lichtin AE.
Thrombotic thrombocytopenic purpura: The role of ADAMTS13. Cleveland
Clinic Journal of Medicine. 2016;83(8):597-603.
8. Bastos MLA, Araujo RMO, Oliveira
DS, Cavalcante ANM, Silva Junior GBD. Thrombotic thrombocytopenic
purpura associated with dengue and chikungunya virus coinfection: case
report during an epidemic period. Revista do Instituto de Medicina
Tropical de Sao Paulo. 2018;60:e48.
9. Koh YR, Hwang S-H, Chang CL, Lee
EY, Son HC, Kim HH. Thrombotic thrombocytopenic purpura triggered by
influenza A virus subtype H1N1 infection. Transfusion and Apheresis
Science. 2012;46(1):25-8.
10. Capecchi M, Mocellin C,
Abbruzzese C, Mancini I, Prati D, Peyvandi F. Dramatic presentation of
acquired TTP associated with COVID-19. Haematologica. 2020.
11. Albiol N, Awol R, Martino R.
Autoimmune thrombotic thrombocytopenic purpura (TTP) associated with
COVID-19. Annals of hematology. 2020;99(7):1673-4.
12. Hindilerden F, Yonal-Hindilerden
I, Akar E, Kart-Yasar K. Covid-19 associated autoimmune thrombotic
thrombocytopenic purpura: Report of a case. Thromb Res. 2020;195:136-8.
13. Sagheer S, Moiz B, Usman M,
Khurshid M. Retrospective Review of 25 Cases of Thrombotic
Thrombocytopenic Purpura in Pakistan. Therapeutic Apheresis and
Dialysis. 2012;16(1):97-103.
14. Chen H, Fu A, Wang J, Wu T, Li Z,
Tang J, et al. Rituximab as first-line treatment for acquired thrombotic
thrombocytopenic purpura. J Int Med Res. 2017;45(3):1253-60.
15. Lim W, Vesely SK, George JN. The
role of rituximab in the management of patients with acquired thrombotic
thrombocytopenic purpura. Blood. 2015;125(10):1526-31.